The abstract is read at the publisher; the summary is JClub's.
In 30 Adenovirus-induced stably-transfected human producer cell clones, higher rAAV producers show decreased amino acid consumption and distinct cholesterol, sphingosine, and ceramide pathway regulation linked to infection timing.
- Why it matters: rAAV therapies need higher titers, but the metabolic signatures that distinguish high- versus low-producing producer clones during adenoviral helper infection remain unclear.
- What they did: The study profiled exometabolites and RNA-Seq across early (first 6 hours) and late adenovirus infection timepoints, integrating RNA-Seq with a genome-scale metabolic model to map pathway shifts.
- The result: Early infection upregulated carnosine biosynthesis-associated pathways versus uninfected growth, while late timepoints increased amino acid release and de novo serine, glycine, and arginine biosynthesis; high producers also reduced cholesterol biosynthesis gene expression and increased HMGCL-linked HMG-CoA degradation, with sphingosine/ceramide gene changes consistent with resistance to cell death and reduced immune signaling.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.